Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + oxaliplatin + tegafur + gimeracil + oteracil potassium
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Apatinib + oxaliplatin + tegafur + gimeracil + oteracil potassium is a combination neoadjuvant therapy being evaluated for the treatment of locally advanced gastric cancer. This regimen combines apatinib, a selective small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR-2) to inhibit tumor angiogenesis, with the SOX chemotherapy regimen. SOX consists of oxaliplatin, a platinum-based agent that forms DNA cross-links to inhibit DNA replication, and S-1, an oral fluoropyrimidine. S-1 is a three-component drug containing tegafur (a prodrug of the antimetabolite 5-fluorouracil), gimeracil (which inhibits the degradation of 5-fluorouracil), and oteracil potassium (which reduces gastrointestinal toxicity). This combination is primarily being studied in clinical trials led by Professor Chang-Ming Huang at Fujian Medical University Union Hospital to improve resectability and pathological complete response rates in gastric cancer patients.
- Brand names
- AitanEloxatinTS-1TS1TS 1Teysuno
- Other names
- apatinib + SOXapatinib + S-1 + oxaliplatin
02
Targets
DPYD (Dihydropyrimidine dehydrogenase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)OPRT (Orotidine 5'-phosphate decarboxylase)
Beyond the preview
Go deeper on apatinib + oxaliplatin + tegafur + gimeracil + oteracil potassium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + oxaliplatin + tegafur + gimeracil + oteracil potassium.